Targeting Central Nervous System B Cells in Progression of Multiple Sclerosis: Is Intrathecal Anti-CD20 a Therapeutic Option?

JAMA Neurol. 2015 Dec;72(12):1407-8. doi: 10.1001/jamaneurol.2015.2869.

Authors

Mahboobeh Fereidan-Esfahani¹, Wolfgang Brück², Martin S Weber³

Affiliations

¹ Institute of Neuropathology, University Medical Centre, Göttingen, Germany2Isfahan Research Committee of Multiple Sclerosis, Isfahan University of Medical Science, Isfahan, Iran.
² Institute of Neuropathology, University Medical Centre, Göttingen, Germany.
³ Institute of Neuropathology, University Medical Centre, Göttingen, Germany3Department of Neurology, University Medical Centre, Göttingen, Germany.

PMID: 26458194
DOI: 10.1001/jamaneurol.2015.2869

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies / administration & dosage*
B-Lymphocytes / drug effects*
B-Lymphocytes / physiology*
Central Nervous System / pathology*
Humans
Injections, Spinal
Multiple Sclerosis / drug therapy*
Receptors, Complement 3d / immunology*

Substances

Antibodies
Receptors, Complement 3d